Expression of Formyl-peptide receptors in human lung carcinoma

Anticancer Research

Volumn 35, Issue 5, 2015, Pages 2769-2774

  Cattaneo, Fabio ^a   Guerra, Germano ^b   Parisi, Melania ^a   Lucariello, Angela ^c   De Luca, Antonio ^c   De Rosa, Nicolina ^c   Mazzarella, Gennaro ^c   Bianco, Andrea ^b   Ammendola, Rosario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Formyl peptide receptors; Gene expression; Lung cancer

Indexed keywords

FORMYLPEPTIDE RECEPTOR; ISOPROTEIN; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LUNG BIOPSY; LUNG CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR CLASSIFICATION; WESTERN BLOTTING; BIOSYNTHESIS; GENETICS; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, FORMYL PEPTIDE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84929667179     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN and Murphy PM: International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formylpeptide receptor (FPR) family. Pharmacol Rev 61: 119-161, 2009.
2. Becker EL, Forouhar FA, Grunnet ML, Boulay F, Tardif M, Bormann BJ, Sodja D, Ye RD, Woska JR Jr. and Murphy PM: Broad immunocytochemical localization of the formylpeptide receptor in human organs, tissues, and cells. Cell Tissue Res 292: 129-135.
3. Ammendola R, Russo L, De Felice C, Esposito F, Russo T and Cimino F: Low-affinity receptor-mediated induction of superoxide by N-formyl-methionyl-leucyl-phenylalanine and WKYMVm in IMR90 human fibroblasts. Free Radic Biol Med 36: 189-200, 2004.
4. Cattaneo F, Parisi M and Ammendola R: Distinct signaling cascades elicited by different formyl Peptide receptor 2 (FPR2) agonists. Int J Mol Sci 14: 7193-7230, 2013.
5. Cattaneo F, Guerra G and Ammendola R: Expression and signaling of formyl-peptide receptors in the brain. Neurochem Res 35: 2018-2026, 2010.
6. Le Y, Murphy PM and Wang JM: Formyl-peptide receptors revisited. Trends Immunol 23: 541-548, 2002.
7. Cattaneo F, Guerra G, Parisi M, De Marinis M, Tafuri D, Cinelli M and Ammendola R: Cell-surface receptors transactivation mediated by G protein-coupled receptors. Int J Mol Sci 15: 19700-19728, 2014.
8. Cattaneo F, Iaccio A, Guerra G, Montagnani S and Ammendola R: NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells. Free Radic Biol Med 51: 1126-1136, 2011.
9. Cattaneo F, Parisi M and Ammendola R: WKYMVm-induced cross-talk between FPR2 and HGF receptor in human prostate epithelial cell line PNT1A. FEBS Lett 587: 1536-1542, 2013.
10. de Laurentiis G, Paris D, Melck D, Montuschi P, Maniscalco M, Bianco A, Sofia M and Motta A: Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate. J Proteome Res 12: 1502-1511, 2013.
11. Mazzarella G, Esposito V, Bianco A, Ferraraccio F, Prati MV, Lucariello A, Manente L, Mezzogiorno A and De Luca A: Inflammatory effects on human lung epithelial cells after exposure to diesel exhaust micron sub particles (PM1.0) and pollen allergens. Environ Pollut 161: 64-69, 2012.
12. Mazzarella G, Lucariello A, Bianco A, Calabrese C, Thanassoulas T, Savarese L, Fiumarella A, Esposito V and De Luca A: Exposure to submicron particles (PM1.0) from diesel exhaust and pollen allergens of human lung epithelial cells induces morphological changes of mitochondria tonifilaments and rough endoplasmic reticulum. In Vivo 28: 557-561, 2014.
13. Esposito V, Lucariello A, Savarese L, Cinelli MP, Ferraraccio F, Bianco A, De Luca A and Mazzarella G: Morphology changes in human lung epithelial cells after exposure to diesel exhaust micron sub particles (PM1.0) and pollen allergens. Environ Pollut 171: 162-167, 2012.
14. Comella P, Frasci G, De Cataldis G Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J and Comella G: Cisplatin/carboplatin+etoposide+vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer 74: 1805-1811, 1996.
15. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Belli M, Iannelli N, Massidda B, Mascia V, Comella G and De Lena M: Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 4: 65-69, 2001.
16. Piantedosi FV, Caputo F, Mazzarella G, Gilli M, Pontillo A, D'Agostino D, Campbell S, Marsico SA and Bianco A: Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol 61: 803-807, 2008.
17. 2+ oscillations in endothelial progenitor cells isolated from umbilical cord blood. Stem Cells Dev 22: 2561-2580, 2013.
18. 2+ concentration. Stem Cells 29: 1898-1907, 2011.
19. 2+ entry is remodelled and controls in vivo angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One 7(9): e42541, 2012.
20. Shapovalov G, Skryma R and Prevarskaya N: Calcium channels and prostate cancer. Recent Pat Anticancer Drug Discov 8: 18-26, 2013.
21. Dragoni S, Laforenza U, Bonetti E, Reforgiato M, Poletto V, Lodola F, Bottino C, Guido D, Rappa A, Pareek S, Tomasello M, Guarrera MR, Cinelli MP, Aronica A, Guerra G, Barosi G, Tanzi F, Rosti V and Moccia F: Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis. PLoS One 9(3): e91099, 2014.
22. 2+ entry in endothelial progenitor cells as a perspective tool to enhance cellbased therapy and adverse tumour vascularisation. Curr Med Chem 19: 5802-5818, 2012.
23. 2+ Signalling in endothelial progenitor cells: a novel means to improve cell-based therapy and impair tumour vascularisation. Curr Vasc Pharmacol 12: 87-105, 2014.
24. Cardarella S and Johnson BE: The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 188: 770-775, 2013.
25. Daniele A, De Rosa A, Nigro E, Scudiero O, Capasso M, Masullo M, de Laurentiis G, Oriani G, Sofia M and Bianco A: Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease. Int J Biochem Cell Biol 44: 563-569, 2012.
26. Corbi G, Bianco A, Turchiarelli V, Cellurale M, Fatica F, Daniele A, Mazzarella G and Ferrara N: Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: Focus on sirtuins. Int J Mol Sci 14: 12696-12713, 2013.
27. Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto T, Taron M and Rosell R: XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 10: 47-52, 2009.
28. Wu JY, Vlastos AT, Pelte MF, Caligo MA, Bianco A, Krause KH, Laurent GJ and Irminger-Finger I: Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Int J Cancer 118: 1215-1226, 2006.
29. Zhang YQ, Bianco A, Malkinson AM, Leoni VP, Frau G, Rosa ND, Andrè PA, Versace R, Boulvain M, Laurent GJ, Atzori L and Irminger-Finger I: BARD1: An independent predictor of survival in non-small cell lung cancer. Int J Cancer 131: 83-94, 2012.
30. Ammendola R, Ruocchio MR, Chirico G, Russo L, De Felice C, Esposito F, Russo T and Cimino F: Inhibition of NADH/NADPH oxidase affects signal transduction by growth factor receptors in normal fibroblasts. Arch Biochem Biophys 397: 253-257, 2002.
31. De Marino S, Cattaneo F, Festa C, Zollo F, Iaccio A, Ammendola R, Incollingo F and Iorizzi M: Imbricatolic acid from Juniperus communis L. prevents cell cycle progression in CaLu-6 cells. Planta Med 77: 1822-1828, 2011.
32. Iaccio A, Cattaneo F, Mauro M and Ammendola R: FPRL1-mediated induction of superoxide in LL-37-stimulated IMR90 human fibroblast. Arch Biochem Biophys 481: 94-100, 2009.
33. Iaccio A, Collinet C, Montesano-Gesualdi N and Ammendola R: Protein kinase C-alpha and -delta are required for NADPH oxidase activation in WKYMVm-stimulated IMR90 human fibroblasts. Arch Biochem Biophys 459: 288-294, 2007.
34. Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, Wang L, Iribarren P, Salcedo R, Howard OM, Farrar W and Wang JM: Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 97: 823-835, 2005.
35. Huang J, Chen K, Huang J, Gong W, Dunlop NM, Howard OM, Bian X, Gao Y and Wang JM: Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis 30:348-355, 2009.
36. Huang J, Chen K, Gong W, Zhou Y, Le Y, Bian X and Wang JM: Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression. Cancer Lett 267: 254-261, 2008.
37. Chakravarti N, Peddareddigari VG, Warneke CL, Johnson MM, Overwijk WW, Hwu P and Prieto VG: Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotype. Am J Dermatopathol 35:184-190, 2013.
38. Gastardelo TS, Cunha BR, Raposo LS, Maniglia JV, Cury PM, Lisoni FC, Tajara EH and Oliani SM: Inflammation and cancer: Role of annexin A1 and FPR2/ALX in proliferation and metastasis in human laryngeal squamous cell carcinoma. PLoS One 9 (12): e111317, 2014.